MarketCap
Prothena Corporation plc PRTA
$ 7.93
0.38%
Facebook
X
Telegram
Prothena Corporation plc ROA Ratio | PRTA
Annual ROA Ratio Prothena Corporation plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -74.69 | -22.36 | -21.11 | -15.43 | 10.99 | -33.38 | -18.53 | -31.2 | -30.87 | -34.81 | -20.93 | -2.35 | -22.47 | -32.03 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.99 | -74.69 | -24.94 |
Quarterly ROA Ratio Prothena Corporation plc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.98 | -38.67 | -44.68 | -54.03 | -63.94 | -43.22 | -23.3 | -11.14 | -8.21 | -5.87 | -22.55 | -10.96 | -19.22 | -29.65 | -28.32 | -22.0 | -4.73 | 9.85 | 7.69 | 13.93 | 4.7 | -21.75 | -35.98 | -33.38 | -29.3 | -24.75 | -20.63 | -18.53 | -17.89 | -18.17 | -26.41 | -31.2 | -36.32 | -41.96 | -33.52 | -30.87 | -31.88 | -30.73 | -35.95 | -34.81 | -30.45 | -27.01 | -22.96 | -20.93 | -18.97 | -17.34 | -12.17 | -2.35 | -4.1 | -5.08 | -11.7 | -24.77 | -28.16 | -29.56 | -30.87 | -32.03 | -6.7 | -7.51 | -8.36 | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.93 | -63.94 | -22.07 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Catalyst Biosciences
CBIO
|
5.95 | $ 13.47 | 4.1 % | $ 1.2 B |  USA |
 |
ARCA biopharma
ABIO
|
-21.58 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-11.69 | - | 4.01 % | $ 150 M |  Canada |
 |
ADiTx Therapeutics
ADTX
|
-260.96 | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
-48.33 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-19.87 | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-35.68 | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
2.08 | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-114.6 | - | - | $ 269 M | USA |
 |
Avenue Therapeutics
ATXI
|
-99.25 | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
-28406.21 | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
8.97 | - | - | $ 96.9 B |  Britain |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1008.51 | - | -2.5 % | $ 5.88 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
EyePoint Pharmaceuticals
EYPT
|
-63.73 | $ 0.36 | 0.59 % | $ 26.4 K | USA |
 |
Bio-Path Holdings
BPTH
|
-254.8 | - | - | $ 100 K | USA |
 |
Cara Therapeutics
CARA
|
-56.78 | - | -3.03 % | $ 260 M | USA |
 |
ChromaDex Corporation
CDXC
|
16.34 | - | -0.88 % | $ 598 M | USA |
 |
Caladrius Biosciences
CLBS
|
-93.47 | - | -16.75 % | $ 25.8 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
36.63 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
36.63 | - | -4.36 % | $ 27 M | USA |
 |
Diffusion Pharmaceuticals
DFFN
|
-117.88 | - | 11.68 % | $ 8.97 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
-44.15 | - | -5.68 % | $ 8.28 M | USA |
 |
Enochian Biosciences
ENOB
|
-35.83 | - | - | $ 40.5 M | USA |
 |
Esperion Therapeutics
ESPR
|
-4.87 | - | - | $ 661 M | USA |
 |
Evofem Biosciences
EVFM
|
1.93 | - | 7.55 % | $ 38.1 M | USA |
 |
Eyenovia
EYEN
|
-87.54 | - | 49.81 % | $ 13.2 M | USA |
 |
FibroGen
FGEN
|
153.4 | - | - | $ 889 M | USA |
 |
Homology Medicines
FIXX
|
48.24 | - | 0.77 % | $ 53.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
-2.85 | - | - | $ 4.47 B | USA |
 |
Frequency Therapeutics
FREQ
|
-103.31 | - | - | $ 528 M | USA |
|
Galecto
GLTO
|
-80.54 | - | - | $ 762 M |  Danmark |
 |
GlycoMimetics
GLYC
|
0.06 | - | 9357.83 % | $ 1.01 B | USA |
 |
Graybug Vision
GRAY
|
-217.51 | - | -11.23 % | $ 9.65 M | USA |
|
Galera Therapeutics
GRTX
|
2071.28 | - | -32.59 % | $ 7.61 M | USA |
 |
Happiness Biotech Group Limited
HAPP
|
-34.54 | - | 1.35 % | $ 17.8 M |  China |
 |
Novavax
NVAX
|
37.42 | $ 10.83 | 10.69 % | $ 1.75 B | USA |
 |
Hepion Pharmaceuticals
HEPA
|
-269.64 | - | -18.79 % | $ 39.3 K | USA |
 |
Hoth Therapeutics
HOTH
|
-164.0 | - | - | $ 18.8 M | USA |
 |
IMARA
IMRA
|
-21.78 | - | 15.96 % | $ 663 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-32.65 | - | - | $ 1.45 B | Britain |
 |
KemPharm
KMPH
|
29.23 | - | -0.34 % | $ 200 M | USA |
 |
Kezar Life Sciences
KZR
|
-73.11 | - | - | $ 53.3 M | USA |
 |
Lixte Biotechnology Holdings
LIXT
|
-47.74 | - | - | $ 63.4 M | USA |
 |
Magenta Therapeutics
MGTA
|
-30.58 | - | -7.74 % | $ 41.6 M | USA |
 |
NovaBay Pharmaceuticals
NBY
|
-6981.52 | - | - | $ 11.3 M | USA |
 |
NeuroBo Pharmaceuticals
NRBO
|
-116.63 | - | 0.43 % | $ 12 M | USA |